Denali Therapeutics

TransportVehicle platform, biotherapeutics, barrier-crossing therapeutics

deliverydeliveringbiologic

denalitherapeutics.com·San Francisco, California, United States·$217M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-TX87

Summary · Eternal Search editorial

Denali Therapeutics TransportVehicle platform, biotherapeutics, barrier-crossing therapeutics

Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. The company invented the TransportVehicle™ platform to enable barrier-crossing therapeutics. Its pipeline spans investigational therapies for neurodegenerative diseases, lysosomal storage disorders and other serious diseases.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite18

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Denali Therapeutics — Near-term readout · Bottom quartile. Derived deterministically from 9 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webdenalitherapeutics.com

HQSan Francisco, California, United States

Publications

28 on file

012026Author Correction: Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution.Nature communications 022026TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonismNature Communications 032026Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.Nature reviews. Drug discovery 042025Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistributionNature Communications 052025Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialNature Communications 062025Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaquesMolecular Neurodegeneration 072025Soluble VCAM-1 May Serve as a Pharmacodynamic CSF Marker to Monitor BACE2 Activity in Non-Human PrimatesMolecular & Cellular Proteomics 082025Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.Science (New York, N.Y.)092025Dual targeting of transferrin receptor and CD98hc enhances brain ...biorxiv 102024TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonismbioRxiv (Cold Spring Harbor Laboratory)112024Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomesCell 122023A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease modelsNature Neuroscience 132023DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress responseeLife 142023Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and PracticeAnnals of Neurology 152023Rab12 is a regulator of LRRK2 and its activation by damaged lysosomeseLife 162023Alzheimer's Targeted Treatments: Focus on Amyloid and InflammationJournal of Neuroscience 172023Rescue of FTLD-associated TDP-43 pathology and neurodegeneration by peripheral AAV-mediated expression of brain-penetrant progranulinbioRxiv (Cold Spring Harbor Laboratory)182023Cleaning crew: Soluble TREM2 mops up complementImmunity 192023DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress ResponsebioRxiv (Cold Spring Harbor Laboratory)202022SARM1 is responsible for calpain-dependent dendrite degeneration ...biorxiv 212022Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiencyThe EMBO Journal 222022LRRK2 Kinase Activity Regulates Parkinson’s Disease-Relevant Lipids at the LysosomebioRxiv (Cold Spring Harbor Laboratory)232022Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microgliaMolecular Neurodegeneration 242021Molecular architecture determines brain delivery of a transferrin-receptor targeted lysosomal enzymebioRxiv (Cold Spring Harbor Laboratory)252021Fibrillar Aβ causes profound microglial metabolic perturbations in a novel APP knock-in mouse modelbioRxiv (Cold Spring Harbor Laboratory)262021Loss of TREM2 reduces hyperactivation of progranulin deficient microglia but not lysosomal pathologybioRxiv (Cold Spring Harbor Laboratory)272019Cell Death and NeurodegenerationCold Spring Harbor Perspectives in Biology 282017The Ste20 Family Kinases MAP4K4, MINK1, and TNIK Converge to Regulate Stress-Induced JNK Signaling in NeuronsJournal of Neuroscience

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Denali Therapeutics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.